OncoMatch/Clinical Trials/NCT05862012

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Is NCT05862012 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ISB 2001 and ISB 2001 for relapsed/refractory multiple myeloma.

Phase 1RecruitingIchnos Sciences SANCT05862012Data as of May 2026

Treatment: ISB 2001 · ISB 2001 — This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Blood counts

adequate hematologic function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Cardiac function

adequate cardiac function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Standford Cancer Institute · Palo Alto, California
University of Chicago Medical Center · Chicago, Illinois
Montefiore Medical Center · The Bronx, New York
University of North Carolina · Chapel Hill, North Carolina
Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify